We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Biomarkers Associated With Cardiovascular Outcomes in Psoriatic Patients

By LabMedica International staff writers
Posted on 22 Mar 2022
Print article
Image: In patients with psoriatic disease, cTnI may reflect the burden of atherosclerosis, independent of traditional cardiovascular risk factors (Photo courtesy of Cardiology Advisor)
Image: In patients with psoriatic disease, cTnI may reflect the burden of atherosclerosis, independent of traditional cardiovascular risk factors (Photo courtesy of Cardiology Advisor)

Psoriasis and psoriatic arthritis (PsA), collectively known as psoriatic disease (PsD), are characterized by excess cardiovascular (CV) morbidity and mortality compared to the general population.

Novel laboratory and imaging biomarkers improve CV risk prediction in the general population, and it has been suggested that they could be combined with conventional scoring systems to optimize CV risk stratification.

A group of Medical Scientists working with the Women’s College Hospital (Toronto, ON, Canada) included in a study, a cohort comprised of participants with a diagnosis of psoriasis without arthritis (PsC) followed since 2006, and psoriatic arthritis (PsA) that have been followed prospectively since 1978 as part of a larger study to investigate disease-related outcomes. Among PsA patients, 98% meet the Classification of Psoriatic Arthritis (CASPAR) criteria. PsC patients are enrolled based on a diagnosis of arthritis conformed by a dermatologist and a rheumatologist.

Annual serum samples have been collected and stored in a biobank since 2002, thus patients entered this study at the date they provided their first serum sample. NT-proBNP (Cobas, Roche Diagnostics, Indianapolis, IN, USA) and high-sensitivity cTnI (ARCHITECT STAT, Abbott Laboratories, Abbott Diagnostics, Abbott Park, IL, USA) were measured in serum samples on automated clinically validated immunoassay analyzers using the manufacturers’ calibrators and quality controls. The limit of detection was 5 pg/mL for NT-proBNP and 1.1 pg/mL for cTnI.

The association between cardiac biomarkers and carotid atherosclerosis was assessed by multivariable regression after adjusting for CV risk factors. In univariate analyses, cTnI (β coefficient, 0.52; 95% confidence interval (CI), 0.3-0.74) and NT-proBNP (β coefficient, 0.24; 95% CI, 0.1-0.39) were associated with carotid total plaque area (TPA). After adjusting for CV risk factors, the association remained statistically significant for cTnI (adjusted β coefficient, 0.21; 95% CI, 0-0.41), but not NT-proBNP. Among all the 1,000 patients in the study who were assessed for CV risk prediction, 64 patients had incident CV events. When comparing a base model with the Framingham Risk Score alone versus expanded models that included the Framingham Risk Score plus cardiac biomarkers, there was no improvement in predictive performance.

The authors concluded that in patients with psoriatic disease (PsD), cTnI may reflect the burden of atherosclerosis, independent of traditional CV risk factors. cTnI and NT-proBNP are associated with incident CV events independent of the Framingham Risk Score (FRS), however, further study of their role in CV risk stratification is warranted. The study was published on march 8, 2022 in the journal Arthritis & Rheumatology.

Related Links:
Women’s College Hospital 
Roche Diagnostics 
Abbott Diagnostics 

Automated ELISA-IFA-BLOT Processor AP 22
Gold Supplier
Saliva Collection Kit
SpeciMAX Stabilized Saliva Collection Kit
Upright Laboratory Freezer
Microbial Infections In-Vitro Diagnostic Solution
Weezion dx

Print article


Molecular Diagnostics

view channel
Image: A new method reliably detects protein changes in blood that are typical of Parkinson`s disease (Photo courtesy of Pexels)

First-Ever Blood Test Detects Parkinson’s Disease

Until now, the diagnosis of Parkinson's disease has been based primarily on typical movement disorders such as muscle stiffness, slower movements and shaking. However, the disease starts up to 20 years... Read more


view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio Acquires ADx NeuroSciences to Speed Development of Neurodegenerative Diseases Diagnostic Tests

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.